Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes

Abstract

Dapagliflozin is a sodium-glucose co-transporter-2 inhibitor that lowers plasma glucose by decreasing its renal reabsorption. The resulting excretion of glucose in the urine (glucosuria) has transformed what was once solely regarded as an adverse facet of diabetes into a potential novel therapeutic strategy. Glucosuria leads to weight loss, due to a… (More)
DOI: 10.2147/CE.S16359

Topics

4 Figures and Tables

Cite this paper

@inproceedings{Chao2012DapagliflozinAE, title={Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes}, author={Edward C. Chao}, booktitle={Core evidence}, year={2012} }